P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND DEATH.

Ítems similars

• Extravascular hemolysis in PNH
  per: Jeff Szer
  Publicat: (2025-10-01)
• P772: LONG-TERM RAVULIZUMAB TREATMENT IN COMPLEMENT INHIBITOR-EXPERIENCED PATIENTS WITH PNH PROVIDES DURABLE CONTROL OF INTRAVASCULAR HEMOLYSIS WITH LOW INCIDENCE OF MAJOR ADVERSE VASCULAR EVENTS AND DEATH.
  per: Austin Kulasekararaj, et al.
  Publicat: (2023-08-01)
• P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD-ON DANICOPAN VS PLACEBO
  per: Jong Wook Lee, et al.
  Publicat: (2023-08-01)
• Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria
  per: Robert A. Brodsky, et al.
  Publicat: (2020-01-01)
• S182: ORAL IPTACOPAN MONOTHERAPY INCREASES PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE VIA CONTROL OF INTRA- AND EXTRAVASCULAR HEMOLYSIS IN ANTI-C5-TREATED PNH PATIENTS WITH ANEMIA
  per: Antonio Maria Risitano, et al.
  Publicat: (2023-08-01)